Pentixapharm Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Public

  • Employees
  • 80

Employees

  • Stock Symbol
  • PTP

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.96
  • (As of Friday Closing)

Pentixapharm General Information

Description

Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Robert Rossle Street 10
  • 13125 Berlin
  • Germany
+49 030
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
FRA
Vertical(s)
Corporate Office
  • Robert Rossle Street 10
  • 13125 Berlin
  • Germany
+49 030

Pentixapharm Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pentixapharm Stock Performance

As of 20-Nov-2026, Pentixapharm’s stock price is $1.96. Its current market cap is $70.3M with 35.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.96 $1.96 $1.46 - $4.14 $70.3M 35.8M 235.60 -$0.58

Pentixapharm Financials Summary

As of 30-Sep-2026, Pentixapharm has a trailing 12-month revenue of $16.3K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (3,049) 33,568 61,489
Revenue 16 105 128 26
EBITDA (14,980) (18,195) 2,242 (6,508)
Net Income (16,050) (18,625) (13,897) (8,266)
Total Assets 8,425 49,168 71,075 81,134
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pentixapharm Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pentixapharm‘s full profile, request access.

Request a free trial

Pentixapharm Patents

Pentixapharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026130747-A1 Antibodies against cd24 Pending 19-Dec-2024
WO-2026082698-A1 Conjugates of modified antibody formats Pending 14-Oct-2024
AU-2025235097-A1 Improved formulation for radiopharmaceutical compounds Pending 15-Mar-2024
WO-2025191100-A1 Improved formulation for radiopharmaceutical compounds Pending 15-Mar-2024
AU-2024402617-A1 Antibodies against cd24 Pending 19-Dec-2023 C07K16/2896
To view Pentixapharm’s complete patent history, request access »

Pentixapharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pentixapharm Acquisitions (1)

Pentixapharm’s most recent deal was a Merger/Acquisition with Glycotope for . The deal was made on 03-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Glycotope 03-Jul-2024 Merger/Acquisition Drug Discovery
To view Pentixapharm’s complete acquisitions history, request access »

Pentixapharm ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

47.06 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Pentixapharm’s complete esg history, request access »

Pentixapharm Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Glycotope Berlin, Germany 2000

Pentixapharm FAQs

  • When was Pentixapharm founded?

    Pentixapharm was founded in 2019.

  • Where is Pentixapharm headquartered?

    Pentixapharm is headquartered in Berlin, Germany.

  • What is the size of Pentixapharm?

    Pentixapharm has 80 total employees.

  • What industry is Pentixapharm in?

    Pentixapharm’s primary industry is Drug Discovery.

  • Is Pentixapharm a private or public company?

    Pentixapharm is a Public company.

  • What is Pentixapharm’s stock symbol?

    The ticker symbol for Pentixapharm is PTP.

  • What is the current stock price of Pentixapharm?

    As of 20-Nov-2026 the stock price of Pentixapharm is $1.96.

  • What is the current market cap of Pentixapharm?

    The current market capitalization of Pentixapharm is $70.3M.

  • What is Pentixapharm’s current revenue?

    The trailing twelve month revenue for Pentixapharm is $16.3K.

  • What is Pentixapharm’s annual earnings per share (EPS)?

    Pentixapharm’s EPS for 12 months was -$0.58.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process